Literature DB >> 18571811

Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase.

Masanori Seimiya1, Takeshi Tomonaga, Kazuyuki Matsushita, Masahiko Sunaga, Masamichi Oh-Ishi, Yoshio Kodera, Tadakazu Maeda, Shigetsugu Takano, Akira Togawa, Hideyuki Yoshitomi, Masayuki Otsuka, Masakazu Yamamoto, Masayuki Nakano, Masaru Miyazaki, Fumio Nomura.   

Abstract

UNLABELLED: Early diagnosis of hepatocellular carcinoma (HCC) greatly improves its prognosis. However, the distinction between benign and malignant tumors is often difficult, and novel immunohistochemical markers are necessary. Using agarose two-dimensional fluorescence difference gel electrophoresis, we analyzed HCC tissues from 10 patients. The fluorescence volumes of 48 spots increased and 79 spots decreased in tumor tissues compared with adjacent nontumor tissue, and 83 proteins were identified by mass spectrometry. Immunoblot confirmed that the expression of clathrin heavy chain (CHC) and Ku86 significantly increased, whereas formiminotransferase cyclodeaminase (FTCD), rhodanese, and vinculin decreased in tumor. The protein expression in tumor and nontumor tissues was further evaluated by immunostaining. Interestingly, CHC and FTCD expression was strikingly different between tumor and nontumor tissues. The sensitivity and specificity of individual markers or a combination for the detection of HCC were 51.8% and 95.6% for CHC, 61.4% and 98.5% for FTCD, and 80.7% and 94.1% for CHC+FTCD, respectively. Strikingly, the sensitivity and specificity increased to 86.7% and 95.6% when glypican-3, another potential biomarker for HCC, was used with FTCD. Moreover, CHC and FTCD were useful to distinguish early HCC from benign tumors such as regenerative nodule or focal nodular hyperplasia, because the sensitivity and specificity of the markers are 41.2% and 77.8% for CHC, 44.4% and 80.0% for FTCD, which is comparable with those of glypican-3 (33.3% and 100%). The sensitivity significantly increased by combination of these markers, 72.2% for CHC+FTCD, and 61.1% for CHC+glypican-3 and FTCD+glypican-3, as 44.4% of glypican-3 negative early HCC were able to be detected by either CHC or FTCD staining.
CONCLUSION: Immunostaining of CHC and FTCD could make substantial contributions to the early diagnosis of HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571811     DOI: 10.1002/hep.22364

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

1.  Discovery of colorectal cancer biomarker candidates by membrane proteomic analysis and subsequent verification using selected reaction monitoring (SRM) and tissue microarray (TMA) analysis.

Authors:  Hideaki Kume; Satoshi Muraoka; Takahisa Kuga; Jun Adachi; Ryohei Narumi; Shio Watanabe; Masayoshi Kuwano; Yoshio Kodera; Kazuyuki Matsushita; Junya Fukuoka; Takeshi Masuda; Yasushi Ishihama; Hisahiro Matsubara; Fumio Nomura; Takeshi Tomonaga
Journal:  Mol Cell Proteomics       Date:  2014-03-31       Impact factor: 5.911

Review 2.  Novel functions of endocytic player clathrin in mitosis.

Authors:  Wenxiang Fu; Qing Jiang; Chuanmao Zhang
Journal:  Cell Res       Date:  2011-06-28       Impact factor: 25.617

3.  Nuclear accumulation of annexin A2 contributes to chromosomal instability by coilin-mediated centromere damage.

Authors:  T Kazami; H Nie; M Satoh; T Kuga; K Matsushita; N Kawasaki; T Tomonaga; F Nomura
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

4.  The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.

Authors:  Osama H Labib; Ola A Harb; Osama H Khalil; Taha A Baiomy; Loay M Gertallah; Rham Z Ahmed
Journal:  J Gastrointest Cancer       Date:  2020-03

5.  SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.

Authors:  Kazuyuki Matsushita; Toshiko Kajiwara; Mai Tamura; Mamoru Satoh; Nobuko Tanaka; Takeshi Tomonaga; Hisahiro Matsubara; Hideaki Shimada; Rei Yoshimoto; Akihiro Ito; Shuji Kubo; Tohru Natsume; David Levens; Minoru Yoshida; Fumio Nomura
Journal:  Mol Cancer Res       Date:  2012-04-11       Impact factor: 5.852

6.  Highlights on the capacities of "Gel-based" proteomics.

Authors:  François Chevalier
Journal:  Proteome Sci       Date:  2010-04-28       Impact factor: 2.480

7.  Increased SSeCKS expression in rat hepatic stellate cells upon activation in vitro and in vivo.

Authors:  Tiangeng You; Yuanzhi Fan; Qi Li; Yong Gao; Yongkang Yang; Zhongxin Zhao; Congjun Wang
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

8.  Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study.

Authors:  Dominik A Megger; Thilo Bracht; Michael Kohl; Maike Ahrens; Wael Naboulsi; Frank Weber; Andreas-Claudius Hoffmann; Christian Stephan; Katja Kuhlmann; Martin Eisenacher; Jörg F Schlaak; Hideo A Baba; Helmut E Meyer; Barbara Sitek
Journal:  Mol Cell Proteomics       Date:  2013-03-05       Impact factor: 5.911

9.  Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Wen Wang; Lan Juan Zhao; Ye-Xiong Tan; Hao Ren; Zhong-Tian Qi
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

10.  Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset.

Authors:  Lishan Wang
Journal:  Tumour Biol       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.